SUPPLEMENTARY MATERIALS

Supplementary 1 Sample Size Estimation and Investigation Process Sample Size Estimation


Our study assumed that a certain risk factor accounts for 20% in the case group and 30% in the control group, $\alpha = 0.05$, $\beta = 0.1$, and 10% non-response rate. A total of 1,085 individuals are required for the case-control study. The formula for calculating the sample size is as follows:

$$n = \left[Z_{1-\alpha/2} \sqrt{(1+1/r) P(1-P)} + Z_{\theta} \sqrt{P_1 \left(1-P_1\right) / r + P_0 \left(1-P_0\right)} \right]^2 / \left(P_1 - P_0\right)^2$$

where $\bar{p} = (P_1 + rP_0)/(1 + r)$ P_1 is the proportion of risk factors in the case group, and P_0 is the proportion of risk factors in the control group, r is the matching ratio between the control and the case group, α is the probability of hypothesis testing type I error, β is the probability of type II error [Zhan SY. Epidemiology. 8th Ed. Beijing: People's Health Publishing House, 2017; 84–5. (In Chinese)].

Supplementary 2 Exploratory Factor Analysis

In the results of EFA, the KMO value was 0.615, and the Bartlett's spherical test yielded χ^2 = 931.821 (df = 36), P < 0.001, suggesting that the index of nucleic acid sampling is suitable for factor analysis. There are three common factors with an initial eigenvalue > 1 in the correlation coefficient matrix, and the cumulative variance contribution rate is 56.843%. After removing the poorly-performed items "nucleic acid sampling frequency" and "type of mask when sampling", the cumulative variance contribution rate rises to 64.189%. The three common factors can be interpreted as: (1) Environmental of sampling site, represented by sampling site location, outdoor/indoor of sampling site and the type of sample site; (2) Sampling practices of sampling personnel, represented by "the frequency of sampling from the right body part" and "sampling from which body part"; (3) Arrangements of sampling site, represented by queuing time and sampling site order, as shown in Supplementary Table S1. The above three factors and nucleic acid sampling frequency were included in the multi-factor analysis.



Supplementary Figure S1. Flow chart of study participants. Participants with or without history of SARS-CoV-2 infection Beijing during November 2022 were considered. The left side of the diagram represents the flowchart for the COVID-19 group (community-found cases). The community-found cases were defined as cases, who could freely transmit the virus through social interactions before quarantine or medical treatment. The right side shows the inclusion flowchart for the non-COVID-19 group and matched through PSM, who living in the same community as the infected person. There was no significant difference in age and gender between those refused and agreed to participate (P > 0.05).

Supplementary Table S1. Factor loading of nucleic acid sampling

Variables	Environmental of sampling site	Sampling practices of sampling personnel	Arrangement of sampling site
Queuing time	0.465	-0.071	0.690
Sampling site arrangement	0.406	-0.473	0.504
Sampling site location	0.559	0.282	-0.294
Outdoor/Indoor of Sampling site	-0.707	-0.310	0.097
Sampled from the right body part	-0.299	0.721	0.275
Sampled from which body part	-0.274	0.671	0.368
Type of sample site	0.777	0.318	-0.140